Cargando…
Endpoint surrogacy in oncology Phase 3 randomised controlled trials
Endpoint surrogacy is an important concept in oncology trials. Using a surrogate endpoint like progression-free survival as the primary endpoint—instead of overall survival—would lead to a potential faster drug approval and therefore more cancer patients with an earlier opportunity to receive the ne...
| Autores principales: | , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7403397/ https://www.ncbi.nlm.nih.gov/pubmed/32451466 http://dx.doi.org/10.1038/s41416-020-0896-5 |